Ludwig Institute for Cancer Research Limited

Other

Csl Limited

B-creative Sweden Ab

University of Michigan

University System of Maryland

Licentia, Ltd.

Helsinki University Licensing Ltd. Oy

Paracrine Therapeutics Ab

Vegenics Pty Limited

Vegenics Limited

Helsinki University Licensing, Ltd.

Flanders Interuniversity Institute for Biotechnology

Hamra Invest Ab

Brain Consultant Nils Gunnar Wahlgren Ab

Ulf Eriksson

Kari Alitalo

Daniel Lawrence

Enming Joe Su

Katri Pajusola

Birgitta Olofsson

Manuel S Yepes

Dudley Strickland

Linda Fredriksson

Xuri Li

Marko Uutela

Karin Aase

Andras Simon

Annika Mehlem

Annelie Falkevall

Anna Romert

Annica Ponten

Carl-Henrik Heldin

Per A Peterson

Eliot L Berson

Taija Makinen

Hioyuji Yamamoto

Andr&aacute;s Simon

Ingrid Nilsson

Arne Oestman

Hong Li

Peter Carmeliet

Ulf G Hellman

Andrew Ewart Scott

Markku Michael Jeltsch

Christer Wernstedt

Aude Le Roux

Milos Pekny

Laura Allan

Erika Bergsten

Ralf Pettersson

Seppo Ylae-Herttuala

Didier Branellec

Tuomas Tammela

Berndt Enholm

Nils Gunnar Wahlgren

Salla Keskitalo

Xuri Lee

Seppo Yla-Herttuala

Terhi Karpanen

Thaddeus P Dryja

Thaddeaus P Dryja

Marko J T Uutela

Kristian Pietras

Pernilla Roswall

Samuel Gebre-Medhin

Desire Collen

Christer Betsholtz

Gabriel Von Euler

Brigitta Olofsson

Claes O Bangvik

Claes Olof Bangvik

Li Xuri

Annica Ponton

The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.

Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen

The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.

Methods and compositions for PDGF-CC inhibition

The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody

A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)

Imatinib can be used in the treatment of stroke in a new dosage regime, where Imatinib is administered to the patient at a dose of 650 mg/day or higher for at least 3 consecutive days, and preferably administered in a starting dose of 1000 mg/day or higher on day 1, and at a dose in the interval of 650 mg/day to 1000 mg/day on the subsequent days. A method for the treatment of stroke, a pharmaceutical composition and a kit of parts is/are also disclosed.

Imatinib for use in the treatment of stroke

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-&#x3b1; antagonist.

Methods and compositions for modulation of blood-neural barrier

The present disclosure provides a method of treating wound healing in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.

Methods of treating wounds in a diabetic subject

The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.

Method of treating diabetic nephropathy in a subject suffering from type 2 diabetes by administering an antibody which inhibits VEGF-B signaling

Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent

Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)

The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.

Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases

Growing community of inventors

Stockholm, Sweden

Ulf Eriksson